NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells

Ya Zhou; Yuanyuan Zhu; Xiaoyan Fan; Chundong Zhang; Yitao Wang; Lian Zhang; Huan Zhang; Tao Wen; Kaina Zhang; Xiao Huo; Xue Jiang; Youquan Bu; Ying Zhang

doi:10.18632/oncotarget.16145

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells

Ya Zhou, Yuanyuan Zhu, Xiaoyan Fan, Chundong Zhang, Yitao Wang, Lian Zhang, Huan Zhang, Tao Wen, Kaina Zhang, Xiao Huo, Xue Jiang, Youquan Bu and Ying Zhang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:33110-33121. https://doi.org/10.18632/oncotarget.16145

Metrics: PDF 2134 views | HTML 3793 views | ?

Abstract

Ya Zhou1,2,*, Yuanyuan Zhu1,2,*, Xiaoyan Fan1,2,*, Chundong Zhang1,2, Yitao Wang1,2, Lian Zhang1,2, Huan Zhang3, Tao Wen4, Kaina Zhang3, Xiao Huo5, Xue Jiang1,2, Youquan Bu1,2 and Ying Zhang1,2

1Department of Biochemistry and Molecular Biology, Chongqing Medical University, Chongqing 400016, China

2Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, China

3College of Pharmacy, Chongqing Medical University, Chongqing 400016, China

4First Clinical College, Chongqing Medical University, Chongqing 400016, China

5College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, China

*These authors contributed equally to this work

Correspondence to:

Ying Zhang, email: [email protected]

Keywords: ovarian cancer, NID1, EMT, metastasis, chemoresistance

Abbreviations: ECM: extracellular matrix; EMT: epithelial-mesenchymal transition; FAK: focal adhesion kinase; MET: mesenchymal-epithelial transition; NID1: nidogen-1

Received: January 09, 2017 Accepted: February 08, 2017 Published: March 13, 2017

ABSTRACT

Nidogen-1 (NID1) has been identified as a novel candidate diagnostic biomarker of ovarian cancer in our previous study. Nevertheless, the role of NID1 in the pathogenesis of ovarian cancer is unclear. In the present study, we demonstrated that NID1 was a mesenchymal associated gene and its high expression was significantly correlated with shorter overall survival of ovarian cancer patients. The ectopic expression of NID1 in OVCAR-3 cells revealed a epithelial-mesenchymal transition (EMT) phenotype accompanied by enhancement of motility, invasiveness and cisplatin resistance, whereas the knockdown of NID1 was sufficient to convert HEY cells into epithelial phenotype with decreased capability of motility, invasiveness and cisplatin resistance. Mechanistic studies disclosed that NID1 activated ERK/MAPK signaling pathway to promote EMT. Collectively, our findings have uncovered the molecular mechanisms of NID1 in promoting ovarian cancer metastasis and chemoresistance, and provide a rationale for the therapeutic potential of NID1 suppression in ovarian cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16145

Publication Alerts

Research Papers:

NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells

Abstract